ACLX-6.90%8.3%
AVBP+52.84%8.3%
CGEM+134.44%8.3%
CRSP-4.51%8.3%
JANX-34.60%8.3%
NRIX+94.87%8.3%
NUVB+164.50%8.3%
NUVL+50.88%8.3%
PTGX+160.56%8.3%
RIGL+123.27%8.3%
RVMD+396.44%8.3%
ZYME+98.17%8.3%
As of Jul 10, 2026, 7:14 AM ET
Biotech '25: Oncology & Immunotherapy Constituents
| Company | Wgt | Premarket % | 1D % | 10D % | MTD % | YTD % | IranWar % | LibDay % | 1Yr % | Mkt Cap |
|---|---|---|---|---|---|---|---|---|---|---|
Revolution Medicines, Inc.RVMD | 8.3% | 0.37% | 0.72% | -0.77% | 1.93% | 139.96% | 87.35% | 452.40% | 396.44% | $40.63B |
Nuvalent, Inc.NUVL | 8.3% | -0.29% | 0.02% | 0.26% | 0.19% | 23.10% | 21.46% | 75.75% | 50.88% | $9.11B |
Protagonist Therapeutics, Inc.PTGX | 8.3% | -3.22% | -1.73% | 13.16% | 9.96% | 57.59% | 49.48% | 185.56% | 160.56% | $8.85B |
CRISPR Therapeutics AGCRSP | 8.3% | 0.15% | -4.83% | -0.02% | 1.29% | 7.44% | -6.32% | 64.79% | -4.51% | $5.43B |
Arcellx, Inc.ACLX | 8.3% | 0.00% | 0.00% | 0.00% | 0.00% | -1.67% | 0.00% | -4.64% | -6.90% | $3.75B |
Nurix Therapeutics, Inc.NRIX | 8.3% | -3.81% | 1.56% | 3.52% | 3.26% | 30.15% | 54.60% | 116.96% | 94.87% | $2.14B |
Nuvation Bio Inc.NUVB | 8.3% | 1.06% | 4.09% | 8.91% | 12.73% | -31.81% | 3.38% | 241.34% | 164.50% | $2.12B |
Zymeworks Inc.ZYME | 8.3% | -5.25% | 1.58% | 12.32% | 5.25% | 2.81% | 16.23% | 127.10% | 98.17% | $1.99B |
ArriVent BioPharma, Inc.AVBP | 8.3% | 0.43% | 0.81% | -2.04% | -2.41% | 67.35% | 46.58% | 87.06% | 52.84% | $1.57B |
Cullinan Therapeutics, Inc.CGEM | 8.3% | 0.05% | -0.27% | -0.22% | 6.37% | 77.58% | 18.58% | 135.04% | 134.44% | $1.13B |
Janux Therapeutics, Inc.JANX | 8.3% | -4.87% | 0.54% | 9.30% | 14.26% | 21.38% | 23.07% | -40.71% | -34.60% | $1.02B |
Rigel Pharmaceuticals, Inc.RIGL | 8.3% | -0.37% | 1.93% | 12.09% | 14.29% | 2.17% | 25.96% | 140.31% | 123.27% | $809.7M |
| Theme return | — | -1.31% | 0.37% | 4.71% | 4.19% | 32.01% | 29.48% | 136.34% | 102.23% | — |
| Average | 8.3% | -1.31% | 0.37% | 4.71% | 5.59% | 33.00% | 28.36% | 131.75% | 102.50% | $6.55B |
| Median | 8.3% | -0.14% | 0.63% | 1.89% | 4.26% | 22.24% | 22.27% | 122.03% | 96.52% | $2.13B |
| Std Dev | 0.0% | 2.18% | 2.07% | 5.69% | 5.65% | 44.13% | 25.66% | 121.11% | 108.97% | $10.65B |
| Min | 8.3% | -5.25% | -4.83% | -2.04% | -2.41% | -31.81% | -6.32% | -40.71% | -34.60% | $809.7M |
| Max | 8.3% | 1.06% | 4.09% | 13.16% | 14.29% | 139.96% | 87.35% | 452.40% | 396.44% | $40.63B |
| % Positive Tickers | 41.67% | 66.67% | 58.33% | 83.33% | 83.33% | 83.33% | 83.33% | 75.00% |
About this theme
Biotech '25: Oncology & Immunotherapy tracks 12 publicly listed stocks in this theme: ACLX, AVBP, CGEM, CRSP, JANX, NRIX, NUVB, NUVL, PTGX, RIGL, RVMD, ZYME. See the constituent table for details.